Gastro One (United States)

Recent papers from Gastro One (United States)

1. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trialHepatology · 2026
2. A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular CarcinomaJournal of Hepatology · 2026
3. Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesHepatology Communications · 2026
4. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitisHepatology Communications · 2024
5. Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases · 2023
6. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisHepatology · 2023
7. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsClinical Gastroenterology and Hepatology · 2022
8. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel DiseaseThe American Journal of Gastroenterology · 2021
9. Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel DiseaseThe American Journal of Gastroenterology · 2021
10. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseThe American Journal of Gastroenterology · 2021
11. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel RecommendationsThe American Journal of Gastroenterology · 2020
12. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHHepatology · 2020
13. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisGastroenterology · 2020
14. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsHepatology · 2019
15. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapyJournal of Medical Virology · 2019
16. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirinLiver International · 2018
17. The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatmentHepatology Communications · 2017
18. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionNew England Journal of Medicine · 2017
19. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialGastroenterology · 2016
20. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeksJournal of Hepatology · 2015